RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
Molecular Oncology
van Helden, Erik J EJ; Angus, Lindsay L; Menke-van der Houven van Oordt, C Willemien CW; Heideman, Daniƫlle A M DAM; Boon, Eline E; van Es, Suzanne C SC; Radema, Sandra A SA; van Herpen, Carla M L CML; de Groot, Derk Jan A DJA; de Vries, Elisabeth G E EGE; Jansen, Maurice P H M MPHM; Sleijfer, Stefan S; Verheul, Henk M W HMW